Study of AZD6094 (Volitinib) in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Third-line Treatment
Status:
Recruiting
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
Volitinib is a potent and selective small molecule c-Met kinase inhibitor. Volitinib was
found to inhibit c-Met kinase at the enzyme and cell levels with IC50s of 4 nM for both
enzyme and Met phosphorylation in the cell. Consistent with its potent enzyme and cell
activity, volitinib was found to inhibit cell growth in vitro against tumors with c-Met gene
amplification in the absence of HGF stimulation with IC50s generally below 10 nM. It also
potently inhibited HGF-stimulated cell proliferation against tumors with c-Met overexpression
or carrying a HGF/c-Met autocrine loop.
This study is a single-arm, phase II study of votilinib in patients with advanced gastric
adenocarcinoma harboring MET amplification as a third line treatment Volitinib 800 mg will be
administered orally once a day for 21 days as one cycle.
To investigate the efficacy of volitinib in patients with advanced gastric adenocarcinoma
harboring MET amplification.